S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
Negative News SentimentNegative News

Bio-Rad Laboratories (BIO) Earnings Date, Estimates & Call Transcripts

$307.00
+2.08 (+0.68%)
(As of 12/1/2023 ET)
Compare
Today's Range
$300.98
▼
$308.27
50-Day Range
$269.37
▼
$365.34
52-Week Range
$261.59
▼
$509.62
Volume
249,303 shs
Average Volume
307,944 shs
Market Capitalization
$8.95 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$533.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Feb. 15Estimated
Actual EPS
(Oct. 26)
$2.33 Missed By -$0.54
Consensus EPS
(Oct. 26)
$2.87
Read Call Transcript
Listen to Call
Latest SEC 10-Q Filing
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

BIO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BIO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Bio-Rad Laboratories Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20232$3.23$3.23$3.23 
Q2 20232$2.56$4.46$3.51 
Q3 20232$2.87$3.47$3.17 
Q4 20232$3.70$4.05$3.88 
FY 20238$12.36$15.21$13.79 
Q1 20241$3.28$3.28$3.28 
Q2 20241$3.79$3.79$3.79 
Q3 20241$3.75$3.75$3.75 
Q4 20241$3.82$3.82$3.82 
FY 20244$14.64$14.64$14.64 
Q1 20251$5.34$5.34$5.34 
Q2 20251$3.98$3.98$3.98 
Q3 20251$4.56$4.56$4.56 

BIO Earnings Date and Information

Bio-Rad Laboratories last announced its quarterly earnings results on October 26th, 2023. The medical research company reported $2.33 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.87 by $0.54. The firm earned $632.10 million during the quarter, compared to the consensus estimate of $689.50 million. Its revenue was down 7.1% on a year-over-year basis. Bio-Rad Laboratories has generated ($5.85) earnings per share over the last year (($5.85) diluted earnings per share). Earnings for Bio-Rad Laboratories are expected to grow by 7.24% in the coming year, from $11.60 to $12.44 per share. Bio-Rad Laboratories has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 15th, 2024 based off prior year's report dates.

Bio-Rad Laboratories Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/15/2024
Estimated)		------- 
10/26/2023Q3 2023$2.87$2.33($0.54)$1.02$689.50 million$632.10 million      
8/3/2023Q2 2023$2.55$3.00+$0.45$45.59$697.96 million$681.10 million      
5/4/2023Q1 2023$3.24$3.34+$0.10$4.36$689.28 million$676.80 million      
2/16/2023Q4 2022$3.45$3.31($0.14)($21.16)$741.01 million$730.29 million      
10/27/2022Q3 2022$2.59$2.60+$0.01$10.72$685.50 million$680.10 million    
7/28/2022Q2 2022$2.46$3.38+$0.92$37.88$664.60 million$691.10 million    
4/28/2022Q1 2022$2.80$4.94+$2.14$122.45$678.00 million$700.10 million      
2/10/2022Q4 2021$2.87$3.21+$0.34$59.01$731.94 million$732.80 million    
10/28/2021Q3 2021$2.30$3.71+$1.41($122.54)$670.36 million$747.00 million    
7/28/2021Q2 2021$2.66$3.54+$0.88($23.24)$610.40 million$715.93 million    
4/29/2021Q1 2021$2.50$5.21+$2.71($21.96)$661.00 million$726.80 million  
2/10/2021Q4 2020$3.30$4.01+$0.71($19.79)$681.80 million$789.84 million  












Bio-Rad Laboratories Earnings - Frequently Asked Questions

When is Bio-Rad Laboratories's earnings date?

Bio-Rad Laboratories has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 15th, 2024 based off last year's report dates. Learn more on BIO's earnings history.

Did Bio-Rad Laboratories beat their earnings estimates last quarter?

In the previous quarter, Bio-Rad Laboratories (NYSE:BIO) missed the analysts' consensus estimate of $2.87 by $0.54 with a reported earnings per share (EPS) of $2.33. Learn more on analysts' earnings estimate vs. BIO's actual earnings.

How can I listen to Bio-Rad Laboratories's earnings conference call?

The conference call for Bio-Rad Laboratories's latest earnings report can be listened to online. Listen to Conference Call

How can I read Bio-Rad Laboratories's conference call transcript?

The conference call transcript for Bio-Rad Laboratories's latest earnings report can be read online. Read Transcript

How can I view Bio-Rad Laboratories's earnings report?

Bio-Rad Laboratories's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does Bio-Rad Laboratories generate each year?

Bio-Rad Laboratories (NYSE:BIO) has a recorded annual revenue of $2.80 billion.

How much profit does Bio-Rad Laboratories generate each year?

Bio-Rad Laboratories (NYSE:BIO) has a recorded net income of -$3.63 billion. BIO has generated -$5.85 earnings per share over the last four quarters.

What is Bio-Rad Laboratories's EPS forecast for next year?

Bio-Rad Laboratories's earnings are expected to grow from $11.60 per share to $12.44 per share in the next year, which is a 7.24% increase.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NYSE:BIO) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -